Page 505 - Read Online

Page 12 of 12 Zeng et al. Hepatoma Res2020;6:43 I http://dx.doi.org/10.20517/2394-5079.2020.29

Copyright
© The Author(s) 2020.

REFERENCES
1. Kimura T, Aikata H, Doi Y, Kimura T, Aikata H, et al. Comparison of stereotactic body radiation therapy combined with or without
transcatheter arterial chemoembolization for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies.
Technol Cancer Res Treat 2018;17:1533033818783450.
2. Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, et al. Phase 2 study of stereotactic body radiotherapy and optional
transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer
2016;122:2041-9.
3. Su TS, Liang P, Lu HZ, Liang J, Gao YC, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular
carcinoma in 132 Chinese patients. J Surg Oncol 2016;113:181-7.
4. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation
for hepatocellular carcinoma. J Clin Oncol 2016;34:452-9.
5. Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, et al. Stereotactic body radiation therapy as an ablative treatment for
inoperable hepatocellular carcinoma. Radiother Oncol 2015;115:211-6.
6. Yamashita H, Onishi H, Matsumoto Y, Murakami N, Matsuo Y, et al. Local effect of stereotactic body radiotherapy for primary and
metastatic liver tumors in 130 Japanese patients. Radiat Oncol 2014;9:112.
7. Lo CH, Huang WY, Lee MS, Lin KT, Lin TP, et al. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients
who failed or were unsuitable for transarterial chemoembolization. Eur J Gastroenterol Hepatol 2014;26:345-52.
8. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective
outcome analysis in 185 patients. Acta Oncol 2014;53:399-404.
9. Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, et al. Stereotactic ablative body radiotherapy for previously untreated solitary
hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:372-9.
10. Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular
carcinoma. PLoS One 2013;8:e79854.
11. Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, et al. High-dose stereotactic body radiotherapy correlates increased local control and
overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013;8:250.
12. Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, et al. Stereotactic body radiation therapy for hepatocellular
carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One 2013;8:e77472.
13. Park JH, Yoon SM, Lim YS, Kim SY, Shim JH, et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment
for small hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1638-42.
14. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to
transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.
15. Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, et al. Tumor response on CT following hypofractionated stereotactic ablative body
radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol 2013;201:W812-20.
16. Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, et al. Tumor response assessment by MRI following stereotactic body
radiation therapy for hepatocellular carcinoma. PLoS One 2017;12:e0176118.
17. Sanuki-Fujimoto N, Takeda A, Ohashi T, Taste-George H, Vogin G, et al. CT evaluations of focal liver reactions following stereotactic
body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver
function. Br J Radiol 2010;83:1063-71.
18. Kimura T, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. The time course of dynamic computed tomographic appearance of radiation
injury to the cirrhotic liver following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 2015;10:e0125231.
19. Park MJ, Kim SY, Yoon SM, Kim JH, Park SH, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of nontumorous
hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed
tomography. PLoS One 2014;9:e90327.
20. Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, et al. Threshold doses for focal liver reaction after stereotactic ablative body
radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-
DTPA. Int J Radiat Oncol Biol Phys 2014;88:306-11.
21. Takeda A, Oku Y, Sanuki N, Kunieda E, Koike N, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic
CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol 2012;104:374-8.
22. Zeng ZC, Seong J, Yoon SM, Cheng JC, Lam KO, et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular
carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer 2017;6:264-74.